It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.
The U.S. IDE clinical trial of the investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott Medical Optics) found that the implant delivered a full range of uncorrected vision and minimized or eliminated the need for spectacle wear in most patients.
A topical treatment that breaks apart disulfide bonds between crystalline lens proteins was shown to increase accommodative amplitude and improve near visual acuity in a randomized, placebo-controlled clinical trial.
Rainbow glare rarely occurs after femto-LASIK surgery and is usually transient. Phototherapeutic keratectomy of the flap undersurface targets the cause of the glare and has been used to immediately resolve symptoms in patients with persistent disabling rainbow glare.
In this first of a two-part series, Arun C. Gulani, MD, MS, explains how approaching keratoconus as a refractive surgery will change the way both ophthalmologists and patients will approach this condition to bring in a new era of not only relieving but also enhancing the lifestyle of this patient population. In Part 2, Dr. Gulani will share strategies and cases of patients with keratoconus with different case scenarios in action.
Steven Dell, MD, and Steve Schallhorn, MD, compared the visual and subjective outcomes in patients who wear contact lenses with those who underwent wavefront-guided LASIK for the correction of myopia and astigmatism.